The beginning of the end of warfarin?
Eikelboom
John W
JW
Hankey
Graeme J
GJ
D000925:Anticoagulants / Q000627:therapeutic use; D001241:Aspirin / Q000494:pharmacology; D001384:Azetidines / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001596:Benzylamines; D005998:Glycine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D011355:Prodrugs / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013917:Thrombin / Q000037:antagonists & inhibitors*; D014859:Warfarin / Q000627:therapeutic use
D000925:Anticoagulants; D001384:Azetidines; D001596:Benzylamines; D010975:Platelet Aggregation Inhibitors; D011355:Prodrugs; C109573:melagatran; C426686:ximelagatran; D014859:Warfarin; D013917:Thrombin; D001241:Aspirin; D005998:Glycine